Results 21 to 30 of about 3,046,243 (224)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Journal of Hematology & Oncology, 2021
In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten ...
F. Pimpinelli, F. Marchesi, G. Piaggio, D. Giannarelli, E. Papa, P. Falcucci, A. Spadea, M. Pontone, S. di Martino, V. Laquintana, Antonia Marina La Malfa, E. D. Di Domenico, O. di Bella, Gianluca Falzone, F. Ensoli, B. Vujovic, A. Morrone, G. Ciliberto, A. Mengarelli   +18 more
semanticscholar   +1 more source

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Blood Cancer Journal, 2021
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major ...
T. Barbui, V. De Stefano, A. Álvarez-Larrán, A. Iurlo, A. Masciulli, A. Carobbio, A. Ghirardi, A. Ferrari, V. Cancelli, E. Elli, M. Andrade-Campos, Mercedes Gasior Kabat, J. Kiladjian, F. Palandri, G. Benevolo, V. García‐Gutiérrez, M. Fox, M. Foncillas, C. Morcillo, E. Rumi, S. Osorio, P. Papadopoulos, M. Bonifacio, Keina Susana Quiroz Cervantes, Miguel Sagues Serrano, G. Carreño-Tarragona, M. Sobas, F. Lunghi, A. Patriarca, B. Elorza, A. Angona, Elena Magro Mazo, S. Koschmieder, G. Carli, B. Cuevas, J. Hernández-Boluda, Emma Lopez Abadia, B. X. Cirici, P. Guglielmelli, M. Garrote, D. Cattaneo, R. Daffini, F. Cavalca, B. Bellosillo, L. Benajiba, N. Curto-Garcia, M. Bellini, S. Betti, C. Harrison, A. Rambaldi, A. Vannucchi   +50 more
semanticscholar   +1 more source

Young platelet millionaires with essential thrombocythemia

American journal of hematology/oncology, 2021
To the Editor: The platelet count threshold for World Health Organization classification system-compliant diagnosis of essential thrombocythemia (ET) is ≥450 × 10/L.
N. Gangat, N. Szuber, Tabinda Jawaid, C. Hanson, A. Pardanani, A. Tefferi   +5 more
semanticscholar   +1 more source

Essential Thrombocythemia in Children and Adolescents

Cancers, 2021
Simple Summary Among chronic Ph-negative myeloproliferative neoplasms, essential thrombocythemia is found in children with low but increasing incidence. The diagnostic and clinical features do not completely overlap with ET of adult age.
M. Putti, I. Bertozzi, M. Randi
semanticscholar   +1 more source

One thousand patients with essential thrombocythemia: the Mayo Clinic experience. [PDF]

Blood Cancer J
We describe 1000 patients with essential thrombocythemia seen at the Mayo Clinic between 1967 and 2023: median age 58 years (18–90), females 63%, JAK2/CALR/MPL-mutated 62%/27%/3%, triple-negative (TN) 8%, extreme thrombocytosis (ExT; platelets ≥1000 ...
Gangat N, Karrar O, Al-Kali A, Begna KH, Elliott MA, Wolanskyj-Spinner AP, Pardanani A, Hanson CA, Ketterling RP, Tefferi A.   +9 more
europepmc   +2 more sources

A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.

Blood, 2020
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily (od), low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of ...
B. Rocca, A. Tosetto, S. Betti, D. Soldati, G. Petrucci, E. Rossi, Andrea Timillero, V. Cavalca, B. Porro, A. Iurlo, D. Cattaneo, C. Bucelli, A. Dragani, M. Di Ianni, Paola Ranalli, F. Palandri, N. Vianelli, E. Beggiato, G. Lanzarone, M. Ruggeri, G. Carli, E. Elli, M. Carpenedo, M. Randi, I. Bertozzi, C. Paoli, G. Specchia, A. Ricco, A. Vannucchi, F. Rodeghiero, C. Patrono, V. De Stefano   +31 more
semanticscholar   +1 more source

Low-Risk Essential Thrombocythemia: A Comprehensive Review

HemaSphere, 2021
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by a persistently elevated platelet count in the absence of a secondary cause.
A. Robinson, A. Godfrey
semanticscholar   +1 more source

Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.

Blood Advances, 2020
Thrombosis is a major cause of morbidity and mortality in polycythemia vera (PV) and essential thrombocythemia (ET). The pathophysiology of thrombosis in these disorders remains unclear, and we hypothesized that upregulation of thrombotic, inflammatory ...
R. Gangaraju, Jihyun Song, Soo Jin Kim, T. Tashi, B. Reeves, K. Sundar, P. Thiagarajan, J. Prchal   +7 more
semanticscholar   +1 more source

Essential thrombocythemia, hemolytic anemia and hepatic cirrhosis: Could there be an association?

Hematology Reports, 2018
Vascular events are the most common clinical complication of essential thrombocythemia, leading to sign and symptoms of this disease. There are various sign and symptoms of essential thrombocythemia, such as thrombosis in artery or vein, and enlarged ...
Nata Pratama Hardjo Lugito, Andree Kurniawan, Yohanes Chandra Kurniawan, Enny Yacobus, Edwin Halim   +4 more
doaj   +1 more source

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

Blood Advances, 2020
Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia (ET) are the 2 entities associated with the most chronic disease course. Leukemic evolution occurs rarely but has a grim prognosis.
D. Luque Paz, Rébecca Jouanneau-Courville, J. Riou, J. Ianotto, F. Boyer, A. Chauveau, Maxime Renard, J. Chomel, E. Cayssials, M. Gallego-Hernanz, C. Pastoret, A. Murati, F. Courtier, M. Rousselet, I. Quintin-Roué, L. Cottin, C. Orvain, S. Thépot, J. Chrétien, Y. Delneste, N. Ifrah, O. Blanchet, M. Hunault-Berger, E. Lippert, V. Ugo   +24 more
semanticscholar   +1 more source